[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"musculoskeletal-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:musculoskeletal-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,77,103,132,164,187,203,226,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100601593","prism-the-primary-care-individual-social-norms-msk-data-dashboard-a-feasibility-trial-100601593",false,"NCT07112508","PRISM: The PRimary Care Individual Social Norms MSK Data Dashboard: a Feasibility Trial","PRISM: The PRimary Care Individual Social Norms MSK Data Dashboard: a Cluster Randomised Feasibility Trial in Clinician Management of Musculoskeletal Patients.","PRISM","Inclusion and Exclusion Criteria for Sites and Individual FCPs Site Inclusion Criteria\n\n* FCPs (First Contact Physiotherapists) must have regular clinical supervision by a more experienced physiotherapist.\n* Health Care Professionals Council (HCPC) registered Physiotherapists.\n* Provide physiotherapy to NHS patients.\n* Able to send monthly data uploads to the UCL Data Safe Haven to be added to the PRISM dashboard.\n\nPatient Inclusion Criteria\n\n* 18 years of age and above.\n* Registered with a GP practice that is a Participant Identification Centre for this study.\n* Consented to provide outcome measures as part of the trial process.\n\nSite Exclusion Criteria\n\n* No clinical supervision by a more experienced physiotherapist available currently or in practice for the FCPs.\n* Community service physiotherapy.\n* Unable to send data to the UCL Data Safe Haven monthly.\n\nPatient Exclusion Criteria\n\n* Non-musculoskeletal (MSK) problem.\n* Insufficient level of English understanding and expression to allow independent completion of assessment instruments.\n* Lacking capacity or unwilling to consent.\n* Patients who attended FCP but were not treated as they were found to have been an inappropriate referral.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\n20 million people in UK have musculoskeletal (MSK) aches and pains. They commonly see their GP about this problem, but practices are so busy that it can mean a long wait for appointments. First Contact Practitioner (FCPs) are now working in the GP practices to see patients with MSK problems instead of their GP. A national evaluation has found this to be working well.\n\nFor FCPs working in GP practices there is more clinical risk. The patients have not been previously screened by a doctor to ensure there is no medical cause for their pain. The Chartered Society of Physiotherapists (CSP) has advised that all FCPs be clinicians with the highest level of experience, known as Advanced Practitioners. However the demand for FCPs far outweighs the number of Advanced Practitioners available so physiotherapists being hired have less experience.\n\nEvidence shows that clinicians of different experience levels have different decision-making strategies which may cause unwarranted variation in care. A new method is needed for oversight and support of the FCPs. Clinical supervision is commonly utilised in the NHS and in physiotherapy teams. It is a space to reflect on a clinician's performance and create learning opportunities.\n\nThis research suggests an individual data dashboard, shared only with individuals and their supervisor, that feeds back a clinician's own decision-making data to them, relative to their peers. For example, the participant is \"in the top 20% of MRI requesters\" or \"in the top 20% of those referring to social prescribing\". This type of feedback is known as 'social norms' feedback. It has been proven to be an effective way to change healthcare workers behaviour. The intervention will be called PRISM: Primary Care Individual Social Norms MSK Data Dashboard.\n\nAims To explore the feasibility of a randomised clinical trial comparing the clinical decision-making behaviour of FCP services using the PRISM Dashboard and a usual service with no clinician feedback.\n\nDesign \\& Methods:\n\nThis research is a feasibility trial, a process to assess whether a future full scale clinical trial within the NHS would work. It will take place across 4 different Primary Care commissioning areas to determine the possibility of recruitment, retention, outcome collection and whether people will use the intervention.\n\nPPIE for this research included one primary care PPI rep, one digital interventions PPI rep and 3 Healthwatch PPI reps. Engaging different PPI sources enabled participation from different social , cultural and ethnic backgrounds.\n\nDissemination I will communicate research updates and outputs in conferences, via social media, blogs, newsletters and podcasts. I will use my own network as well as the reach of collaborators in this work, ie. Healthwatch, NHS England\u002FImprovement, The (CSP), the physiotherapy digital network, Keele University and UCL research networks.",[27],"Musculoskeletal Disorders",[29,30,31,32,33,34],"Musculoskeletal","Primary Care","First Contact Physiotherapy","First Contact Practitioner","Digital Health","Behaviour change","RECRUITING","2026-06-01",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":39},"2026-04-01",{"date":43,"type":21},"2027-11-01",{"name":45,"class":46},"University College, London","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100550749","phase-2-platelet-rich-plasma-injections-in-young-and-old-human-subjects-100550749","NCT06451120","Platelet Rich Plasma Injections In Young And Old Human Subjects","Study of Platelet Rich Plasma (PRP) Injections With Symptomatic Knee Osteoarthritis for Biomarker Exploration in Young and Old Human Subjects","PRP-KOBE","Inclusion Criteria\n\n1. Grade 1-3 KL score will be recruited;\n2. Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee;\n3. Have symptomatic complaints from osteoarthritis pain in no other joint affecting the hips, ankles or unaffected knee;\n4. Will be able to attend and perform physical therapy.\n5. English-speaking\n\nExclusion Criteria\n\n1\\. Patients will be excluded if:\n\n1. Received injection therapy for knee osteoarthritis in the past 6 months\n2. Have signs of concomitant osteoarthritis of 1 or more other major joints of the lower extremities that impair their daily activity level\n3. History of septic arthritis\n4. Have underwent a previous knee surgery specifically for osteoarthritis or osteochondral defects less than 1 year before randomization (i.e. autograft or allograft surgery\n5. High tibial osteotomy, partial knee replacement, patellar resurfacing), total knee replacement or existing surgical hardware in the knee\n6. Patient with platelet disorders, bleeding disorder\n7. Patient with rheumatologic disease, automimmune disorder, immunocompromised status, active history of cancer\n8. Patient taking Chemotherapy, need for regular prednisone or antiinflammatory used\n9. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n10. Uncontrolled illness, physical disability, or other contraindication to aerobic exercise training including, but not limited to:\n\ni. Acute myocardial Infarction (within 5 days of any planned study procedure); ii. Unstable angina; iii. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise; iv. Recurrent syncope; v. Active endocarditis; vi. Acute myocarditis or pericarditis; vii. Symptomatic severe aortic stenosis; viii. Uncontrolled heart failure; ix. Acute (within 3 months) pulmonary embolus or pulmonary infarction; x. Thrombosis of lower extremities; xi. Suspected dissecting aneurysm; xii. Uncontrolled asthma; xiii. Pulmonary edema; xiv. Room air desaturation at rest ≤85%; xv. Respiratory failure; xvi. Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (ie infection, renal failure, thyrotoxicosis); and xvii. Mental impairment leading to inability to cooperate.",true,"70 Years",{"count":20,"type":21},[60],"PHASE2","This is a randomized, double-blind, placebo-controlled phase 2 study with a secondary crossover phase at the end of the initial trial to ensure all subjects receive one PRP injection. The goal is to identify what proteins change in the blood following repeated intraarticular knee PRP injections in patients with knee osteoarthritis. The objective is to determine the protein changes resulting from a single autologous PRP injection (5 mL) in comparison to a normal saline control.\n\nAbout 60 subjects will take part in this study by two age groups at UCSF into the following arms: Arm A: PRP injection; Arm B: normal saline injection control. The study aims to demonstrate what benefits PRP has on knee osteoarthritis and methods to best achieve biologic effects. Subjects with a diagnosis of knee osteoarthritis ages 18-45 and 46-70 years old presenting to a University Based sports medicine clinic will be screened for potential eligibility. Subjects who meet all qualifying requirements will be recruited from UCSF's orthopedic and primary care clinics.\n\nSubjects will be on study for up to 26 weeks Screening: up to 14 days Treatment: injection of PRP or normal saline; subjects can cross over at week 12 to a PRP if originally in the control injection group Follow-up: 2 weeks post-baseline injection, 12 weeks postbaseline, (14 weeks if crossover patient), 26 weeks.",[63,64,27],"Osteoarthritis","Articular Cartilage",[66],"Platelet-rich plasma (PRP)","2026-03-18",{"date":69,"type":39},"2026-03-19",{"date":71,"type":39},"2024-06-01",{"date":73,"type":21},"2027-02-16",{"name":75,"class":46},"University of California, San Francisco",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100622349","workstation-ergonomics-program-at-al-baha-university-100622349","NCT07382466","Workstation Ergonomics Program at Al-Baha University","Workstation Ergonomics Intervention to Reduce Musculoskeletal Symptoms Among University Employees","ERG-ABU","Inclusion Criteria:\n\n* Adults aged 18-55 years.\n* Affiliated with Al-Baha University (staff, or faculty) and regularly use a computer workstation (≥3 hours\u002Fday or ≥15 hours\u002Fweek).\n* Able to read and complete the online questionnaire and provide informed consent.\n\nExclusion Criteria:\n\n* Current severe musculoskeletal disorder or recent major injury\u002Fsurgery that markedly limits daily activities or requires ongoing medical treatment.\n* Diagnosed neurological or rheumatologic condition affecting the musculoskeletal system (e.g., severe radiculopathy, inflammatory arthritis).\n* Pregnancy (if you prefer to exclude it).\n* Participation in another ergonomics intervention program during the study period.","55 Years",{"count":87,"type":21},100,[24],"This study evaluates a workstation ergonomics program at Al-Baha University aimed at reducing work-related musculoskeletal symptoms among university employees who use computers regularly. The program includes an ergonomics self-assessment of the workstation, individualized guidance on proper workstation setup and posture, and practical recommendations to improve daily work habits. Participants will be followed for approximately four weeks, and changes in musculoskeletal symptoms and related outcomes will be assessed before and after the program, compared with a usual-practice control group.",[91,27,92],"Work-Related Musculoskeletal Disorders","Occupational Musculoskeletal Disorders","NOT_YET_RECRUITING","2026-02-01",{"date":96,"type":39},"2026-02-04",{"date":98,"type":21},"2026-02-10",{"date":100,"type":21},"2026-04-10",{"name":102,"class":46},"Al-Baha University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":76},"100620282","mobile-app-assisted-home-exercise-for-musculoskeletal-disorders-100620282","NCT07355595","Mobile App-Assisted Home Exercise for Musculoskeletal Disorders","The Effect of the Mobile App-Assisted Home Exercise Program on Clinical Outcomes in Patients With Musculoskeletal Disorders","Inclusion Criteria:\n\n* Aged 18 years and above\n* Presenting with musculoskeletal disorders leading to pain in the neck, shoulder, low back, or knee\n* Scoring 3 or higher on the Numeric Pain Rating Scale\n\nExclusion Criteria:\n\n* Diagnosis of malignant tumors\n* Presence of serious systemic or neurological conditions that may interfere with assessment or treatment, such as uncontrolled hypertension, serious cardiac diseases, or Parkinson's disease\n* Inability to use a mobile smartphone\n* Pregnancy",{"count":111,"type":21},30,[24],"Overview This study evaluates the effectiveness of a dedicated mobile health (mHealth) application in supporting home exercise programs for patients with musculoskeletal disorders, such as neck, shoulder, back, or knee pain. The research aims to address the widespread challenge of low patient adherence to unsupervised home-based exercises.\n\nStudy Design The project employs a dual-methodology approach:\n\nClinical Trial: 30 participants presenting with neck, shoulder, back, or knee pain will be randomly assigned to either an app-assisted group or a traditional home exercise group. Both groups will undergo 4 weeks of physiotherapy. The study will compare pain intensity, physical function, and exercise adherence between the two cohorts.\n\nRetrospective Analysis: To complement the trial, the study will analyze a large-scale database containing approximately 700,000 anonymized real-world data entries. This analysis aims to observe real-time pain fluctuations before and after exercise sessions within routine clinical settings.\n\nGoal The primary objective is to determine if integrating mHealth technology into traditional rehabilitation can enhance clinical outcomes and improve patient adherence to home-based exercise routines.",[27,115,116,117,118],"Low Back Pain","Neck Pain","Shoulder Pain","Knee Pain",[120,121,122],"e-Health","Mobile Applications","Home Exercise Program","2026-01-12",{"date":125,"type":39},"2026-01-21",{"date":127,"type":21},"2026-01-15",{"date":129,"type":21},"2026-09-15",{"name":131,"class":46},"National Yang Ming Chiao Tung University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":163},"100578283","observational-prospective-pmcf-study-to-confirm-performance-and-safety-of-intelect-devices-in-real-world-100578283","NCT06809283","Observational Prospective PMCF Study to Confirm Performance and Safety of Intelect® Devices in Real World","Observational Prospective Post Market Clinical Follow-up (PMCF) Study to Confirm the Performance and Safety of the Chattanooga Intelect® Devices in Real World Use","INTELECT","Inclusion Criteria:\n\n1. Patients with musculoskeletal and skeletal muscle deficit disorders assigned to be treated with any of the Intelect® devices according to the current clinical practice at the selected sites and based on the opinion of the Investigator.\n2. Patient male or female with age ≥18 years old.\n3. Patient able to provide written informed consent. For France only: To be affiliated to the social security system or to be beneficiary of such system\n\nExclusion Criteria:\n\n1. Patients participating in another clinical study or who have completed a clinical study less than 30 days prior to enrollment.\n2. Patients who for any reason e.g. significant co-morbidities or other reasons, are considered by the Investigator unsuitable for study participation.",{"count":141,"type":21},144,"OBSERVATIONAL","DJO UK Ltd (ENOVIS) is conducting this study to confirm the performance and safety of the Chattanooga Intelect® devices in real world use. This study will record post market clinical data on the use of a number of MDR-CE marked devices that are part of the Chattanooga Intelect® device family to ensure the continued acceptability of the benefit-risk ratio, and to identify possible systematic misuse or off-label use of the devices (Intelect® Mobile 2 Combo, Intelect® Mobile 2 Ultrasound, Intelect® Mobile 2 Electrotherapy (Stim), Intelect® Transport 2 Combo and Intelect® Transport 2 Ultrasound).",[27,145,146],"Skeletal Disorder","Muscle Disorder",[148,149,150,151,152],"TENS","NMES","Ultrasound","Pain","ROM","2025-11-14",{"date":155,"type":39},"2025-11-17",{"date":157,"type":39},"2025-03-10",{"date":159,"type":21},"2026-12",{"name":161,"class":162},"DJO UK Ltd","INDUSTRY",4,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100605659","analysis-of-neuromodulation-as-a-complementary-treatment-to-evidence-based-clinical-intervention-in-subjects-with-musculoskeletal-pathology-of-the-upper-limb-a-double-blind-randomized-clinical-trial-100605659","NCT07165392","Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Upper Limb: a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n* Participants in the study will be men and women of working age, diagnosed with musculoskeletal disorders of the upper limb, and who have not yet received physical therapy.\n\nExclusion Criteria:\n\n* Have undergone surgery.\n* Those who refuse to participate in this study.\n* Patients who present muscular atrophy in the upper limb due to a pathology of the latter.\n* Medical conditions that are contraindications for neuromodulation therapy","60 Years",{"count":172,"type":21},120,[24],"This project aims to analyze the use of neuromodulation within a treatment protocol for musculoskeletal conditions of the upper limb, as well as to determine the difference between two and three sessions per week. Study participants will be divided into four intervention groups: the first will receive two sessions per week for a period of six months, while the second will receive three sessions per week for the same period. The treatment protocol will consist of therapeutic physical exercise focused on the muscles and joints of the lower limb, stretching of the involved muscles, and neuromodulation of the brachial plexus nerve root, which innervates the affected structures. The third and fourth intervention groups will receive the same treatment as mentioned above, but without neuromodulation. The third group will receive three sessions per week, while the second group will receive two sessions per week. Two different types of measurement variables will be used: objective variables will be used to measure range of motion and muscle strength. Subjective variables will also be used through validated questionnaires, covering physical activity, health-related quality of life, upper limb function, and a visual analog scale for pain perception.",[176,177,27],"Neuromodulation","Upper Limb","2025-09-02",{"date":180,"type":39},"2025-09-10",{"date":182,"type":21},"2025-10-01",{"date":184,"type":21},"2027-03-31",{"name":186,"class":46},"University of Malaga",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":202,"locationsCount":4},"100605658","analysis-of-neuromodulation-as-a-complementary-treatment-to-evidence-based-clinical-intervention-in-subjects-with-musculoskeletal-pathology-of-the-lower-limb-a-double-blind-randomized-clinical-trial-100605658","NCT07165379","Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Lower Limb: a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n* Participants in the study will be men and women of working age, diagnosed with musculoskeletal disorders of the lower limb, and who have not yet received physical therapy.\n\nExclusion Criteria:\n\n* Have undergone surgery.\n* Those who refuse to participate in this study.\n* Patients who present muscular atrophy in the lower limb due to a pathology of the latter.\n* Medical conditions that are contraindications for neuromodulation therapy",{"count":194,"type":21},64,[24],"This project aims to analyze the use of neuromodulation within a treatment protocol for musculoskeletal conditions of the lower limb, as well as to determine the difference between two and three sessions per week. Study participants will be divided into four intervention groups: the first will receive two sessions per week for a period of six months, while the second will receive three sessions per week for the same period. The treatment protocol will consist of therapeutic physical exercise focused on the muscles and joints of the lower limb, stretching of the involved muscles, and neuromodulation of the nerve root of the lumbosacral plexus, which innervates the affected structures. The third and fourth intervention groups will receive the same treatment as mentioned above, but without neuromodulation. The third group will receive three sessions per week, while the second group will receive two sessions per week. Two different types of measurement variables will be used: objective variables will be used to measure range of motion and muscle strength. Subjective variables will also be used through validated questionnaires, covering physical activity, health-related quality of life, lower limb function, and a visual analog scale for pain perception.",[176,198,27],"Lower Limb",{"date":180,"type":39},{"date":182,"type":21},{"date":184,"type":21},{"name":186,"class":46},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":76},"100603533","effect-and-cost-of-a-physiotherapy-led-care-model-in-emergency-departments-for-patients-with-minor-musculoskeletal-injuries-100603533","NCT07137754","Effect and Cost of a Physiotherapy-led Care Model in Emergency Departments for Patients With Minor Musculoskeletal Injuries","Effect and Cost-effectiveness of a Physiotherapy-led Care Model for Patients Referred to an Emergency Department Due to Musculoskeletal Injuries: A Multicentre Quasi-randomized Clinical Trial","Inclusion Criteria:\n\n* Musculoskeletal pain and injury to the upper or lower extremities\n* Triaged non-urgent (blue) in the emergency department\n* Speaks and understands Danish\n\nExclusion Criteria:\n\n* High velocity trauma\n* Cognitively unable to participate\n* Non-malignant conditions (cancer, inflammation, infection)",{"count":211,"type":21},800,[24],"Both in Denmark and internationally, emergency departments have been overwhelmed for several years by a growing number of patients, combined with a shortage of doctors and nurses. This problem is expected to continue because the number of elderly people with multiple health problems is increasing. To keep providing good quality care in emergency departments, we need to consider new ways of organizing treatment.\n\nIn Canada, Australia, and the UK, some hospitals have tried a model where specially trained physiotherapists examine and treat patients who come in with muscle and joint injuries and pain. Since these patients make up about 25% of all those referred to emergency departments, this model could help take some pressure off doctors and nurses. That way, doctors and nurses can spend more time caring for seriously ill patients who need urgent help.\n\nSeveral studies on these physiotherapist-led models show benefits for both patients and the healthcare system. Patients report being more satisfied and better informed about their injury and treatment. They wait less, have fewer unnecessary tests, and need fewer repeat visits to the emergency department.\n\nHowever, similar studies have never been done in Scandinavia, even though some Danish emergency departments have tested similar models. Healthcare systems and the education of physiotherapists differ between Scandinavian countries and the countries mentioned above. So, we don't know if we would see the same benefits here. Also, there has been no research on whether this model is cost-effective, which is important for decision-makers when planning future healthcare budgets.\n\nWith this research project, we want to test a model in Danish hospitals where specially trained physiotherapists take care of examining, treating, and discharging patients with muscle and joint pain and injuries. We will look at how this model affects patient experiences (like pain and satisfaction) and clinical outcomes (like repeat emergency visits and use of imaging tests), compared to the usual practice where doctors handle these patients. We will also study whether the model is cost-effective, meaning whether the benefits of using this approach are worth the costs, or even greater than the costs.\n\nThe study will be conducted at 4-5 hospitals, where a total of 800 patients with minor musculoskeletal injuries will be included in connection with their visit at the emergency department. Patients will receive questionnaires at 1, 4, 12 and 26 weeks after injury regarding patient reported outcomes. Register data will be retrieved at 26 weeks regarding the patients' health care use during follow-up.",[27,215,216],"Emergency Care","Physiotherapy","2025-08-22",{"date":219,"type":39},"2025-08-28",{"date":221,"type":39},"2025-08-15",{"date":223,"type":21},"2028-03-01",{"name":225,"class":46},"Aarhus University Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":56,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":237,"studyType":142,"phases":4,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":4},"100570625","prevalence-of-musculoskeletal-disorders-100570625","NCT06709677","Prevalence of Musculoskeletal Disorders","Prevalence of Musculoskeletal Disorders Among Egyptian Students in the Faculty of Applied Arts","Inclusion Criteria:\n\n1. 250 Egyptian students from different Faculties of Applied Art.\n2. Age (20-22) years old\n3. both genders will be included.\n\nExclusion Criteria:\n\n1. Obesity.\n2. Pregnancy.\n3. Patients who had history of any other neuropathy.\n4. Unstable medical condition.\n5. Other neurological disorders causing pain as lumbar plexopathy, spinal stenosis, and spinal nerve root compression.\n6. History of central nervous system primary or metastatic malignancy\n7. student having any musculoskeletal problems due to other causes as accidents or a previous operation.","20 Years","22 Years",{"count":236,"type":21},250,"4 Weeks","This observational cross-sectional study aims to determine the prevalence of musculoskeletal disorders (MSDs) among Egyptian students in the Faculty of Applied Arts. Using the Arabic version of the extended Nordic Musculoskeletal Questionnaire (NMQ-E), the study will assess the prevalence, distribution, and associated factors of musculoskeletal symptoms over the last 12 months and 7 days. A sample of 250 participants, aged 20-22 years and of both genders, will be recruited. Exclusion criteria include obesity, pregnancy, history of neuropathy, unstable medical conditions, or trauma-related musculoskeletal problems. The results will provide insights into MSD prevalence and help guide interventions for this population.",[27,240],"Among Egyptian Students in the Faculty of Applied Arts",[242,27,243,244],"Prevalence","Egyptian Students","Faculty of Applied Arts","2024-11-28",{"date":247,"type":39},"2024-12-03",{"date":249,"type":21},"2025-01-05",{"date":251,"type":21},"2025-06-30",{"name":253,"class":46},"Cairo University",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":265,"conditions":266,"keywords":277,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":76},"100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052","NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",{"count":262,"type":21},5000,[264,60],"PHASE1","This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[267,268,269,270,27,271,272,273,274,275,276],"Autoimmune Diseases","Cardiovascular Disorders","Diabetes Complications","Integumentary Disease","Neurodegenerative Disorders","Neurologic Disorders","Pulmonary Disorders","Sexual Dysfunction","Urologic Disorders","Viral Illness",[278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Neurodegenerative Diseases","Central Nervous System Diseases","Tauopathies","Brain Diseases","Dementia","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Nervous System Diseases","Alzheimer Disease","Musculoskeletal Diseases","Cardiovascular Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":307,"type":39},"2022-04-29",{"date":309,"type":39},"2020-07-09",{"date":311,"type":21},"2030-12-09",{"name":313,"class":162},"Thomas Advanced Medical LLC"]